US Bancorp DE Purchases 1,510 Shares of Dianthus Therapeutics, Inc. $DNTH

US Bancorp DE increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 2,013.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,585 shares of the company’s stock after purchasing an additional 1,510 shares during the quarter. US Bancorp DE’s holdings in Dianthus Therapeutics were worth $29,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. TCG Crossover Management LLC acquired a new position in shares of Dianthus Therapeutics in the 4th quarter worth approximately $32,735,000. Braidwell LP increased its holdings in Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock valued at $26,304,000 after purchasing an additional 712,902 shares in the last quarter. Vestal Point Capital LP increased its holdings in Dianthus Therapeutics by 172.2% during the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock valued at $23,435,000 after purchasing an additional 680,000 shares in the last quarter. Octagon Capital Advisors LP raised its position in Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after purchasing an additional 363,500 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Dianthus Therapeutics in the fourth quarter worth $3,924,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Trading Up 3.2%

Dianthus Therapeutics stock opened at $23.42 on Thursday. The company has a market cap of $753.89 million, a PE ratio of -7.21 and a beta of 1.43. Dianthus Therapeutics, Inc. has a 1 year low of $13.36 and a 1 year high of $32.27. The company’s 50-day moving average is $19.73 and its two-hundred day moving average is $20.02.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analyst Upgrades and Downgrades

DNTH has been the subject of a number of research analyst reports. William Blair began coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Finally, Robert W. Baird decreased their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $53.00.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.